Asp Isotopes INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ASP Isotopes Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, corporate governance, and director information.
NASDAQ
ASP Isotopes Inc. subsidiary, Tetra 4 Proprietary Limited, has entered into a ZAR 160.7 million loan agreement with the Industrial Development Corporation of South Africa Limited to fund the acquisition of LNG dispensing plant and equipment.
NASDAQ
ASP Isotopes Inc. files an amendment to its 2024 Annual Report on Form 10-K/A to include information previously omitted regarding directors, executive compensation, and corporate governance.
NASDAQ
ASP Isotopes Inc. reports a net loss for 2024 while advancing commercial production of enriched isotopes and pursuing HALEU production.
NASDAQ
ASP Isotopes has filed an amendment to its annual report to correct a typographical error regarding the effectiveness of its internal controls over financial reporting, which were deemed not effective due to previously disclosed material weaknesses.
NASDAQ
ASP Isotopes Inc. has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.
NASDAQ
ASP Isotopes Inc.'s recent 10-K filing outlines the company's capital structure, including authorized shares and anti-takeover provisions, while also detailing recent business activities and financial results.